肿瘤指南

订阅

MedSci主页 / 所有栏目 / 肿瘤指南

外周血HER2基因扩增检测(数字PCR法)在抗HER2治疗中的应用共识

2022-01-27 复旦大学附属肿瘤医院 中国癌症杂志

抗Her2治疗外周血HER2基因扩增检测

乳腺癌患者中20%~30%人表皮生长因子受体2（human epidermal growth factor receptor 2,HER2）阳性,该类型乳腺癌具有恶性程度高、侵袭性强、预后差等特点。

中文标题：

外周血HER2基因扩增检测(数字PCR法)在抗HER2治疗中的应用共识

发布机构：

复旦大学附属肿瘤医院

发布日期：

2022-01-27

简要介绍：

乳腺癌患者中20%~30%人表皮生长因子受体2（human epidermal growth factor receptor 2,HER2）阳性,该类型乳腺癌具有恶性程度高、侵袭性强、预后差等特点。抗HER2靶向药物能有效地降低HER2阳性乳腺癌患者复发和转移的风险,延长生存期,改善预后,HER2状态是乳腺癌重要的预后评估指标和抗HER2治疗选择的主要预测指标。众多国内外指南和共识均推荐可获取肿瘤组织的乳腺癌患者采用免疫组织化学法（immunohistochemistry,IHC）检测HER2受体蛋白的水平,采用荧光原位杂交法（fluorescence in situ hybridization,FISH）检测HER2基因的扩增水平。 

相关资料下载：
[AttachmentFileName(sort=1, fileName=外周血HER2基因扩增检测(数字PCR法)在抗HER2治疗中的应用共识.pdf)] GetToolGuiderByIdResponse(projectId=1, id=f97061c002353a8f, title=外周血HER2基因扩增检测(数字PCR法)在抗HER2治疗中的应用共识, enTitle=, guiderFrom=中国癌症杂志, authorId=0, author=, summary=乳腺癌患者中20%~30%人表皮生长因子受体2（human epidermal growth factor receptor 2,HER2）阳性,该类型乳腺癌具有恶性程度高、侵袭性强、预后差等特点。, cover=https://img.medsci.cn/2022212/1644671490371_5579292.png, journalId=0, articlesId=null, associationId=2410, associationName=复旦大学附属肿瘤医院, associationIntro=复旦大学附属肿瘤医院, copyright=0, guiderPublishedTime=Thu Jan 27 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #333333;">乳腺癌患者中20%~3</span><span style="color: #333333;">0%人表皮生长因子受体2（human epidermal growth factor receptor 2,HER2）阳性,该类型乳腺癌具有恶性程度高、侵袭性强、预后差等特点。抗HER2靶向药物能有效地降低HER2阳性乳腺癌患者复发和转移的风险,延长生存期,改善预后</span><span style="color: #333333;">,HER2状态是乳腺癌重要的预后评估指标和抗HER2治疗选择的主要预测指标。众多国内外指南和共识</span><span style="color: #333333;">均推荐可获取肿瘤组织的乳腺癌患者采用免疫组织化学法（immunohistochemistry,IHC）检测HER2受体蛋白的水平,采用荧光原位杂交法（fluorescence in situ hybridization,FISH）检测HER2基因的扩增水平。&nbsp;</span></p>, tagList=[TagDto(tagId=60205, tagName=抗Her2治疗), TagDto(tagId=122871, tagName=外周血HER2基因扩增检测)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3800, appHits=42, showAppHits=0, pcHits=404, showPcHits=3758, likes=1, shares=18, comments=2, approvalStatus=1, publishedTime=Sun Feb 13 15:08:00 CST 2022, publishedTimeString=2022-01-27, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Sat Feb 12 21:12:44 CST 2022, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Thu Jan 04 02:01:25 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=外周血HER2基因扩增检测(数字PCR法)在抗HER2治疗中的应用共识.pdf)])
外周血HER2基因扩增检测(数字PCR法)在抗HER2治疗中的应用共识.pdf
下载请点击：
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1204286, encodeId=5b2b1204286f1, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9a56561503, createdName=ms8000002023252547, createdTime=Sun Mar 20 10:25:10 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193103, encodeId=8542119310326, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Sun Feb 13 21:33:36 CST 2022, time=2022-02-13, status=1, ipAttribution=)]
    2022-03-20 ms8000002023252547

    好

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1204286, encodeId=5b2b1204286f1, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9a56561503, createdName=ms8000002023252547, createdTime=Sun Mar 20 10:25:10 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193103, encodeId=8542119310326, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Sun Feb 13 21:33:36 CST 2022, time=2022-02-13, status=1, ipAttribution=)]
    2022-02-13 ms3000000637975859

    非常好

    0